Drugs / Y Zevalin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01538472 | Sep 2003 → Nov 2011 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00732498 | May 2006 → Oct 2018 | lymphoma | University of Arizona | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y Zevalin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01538472 ↗ |
| Action | Deplete | “the radiation particle destroys the lymphoma cell” NCT01538472 ↗ |
| Modality | Protein / enzyme biologic | “90Y Zevalin is also an antibody made from mouse proteins.” NCT01538472 ↗ |
| Route | Intravenous | “Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.” NCT00732498 ↗ |